The prevalence of diabetes in Europe and the world is growing rapidly, with more than 9 million people in the United Kingdom, Germany, and France alone expected to have diabetes by 2030. This would be up 50% from the more than 6 million afflicted with the disease today in these countries, according to the World Health Organization.
With millions of patients needing treatment for the two types of diabetes, it comes as no surprise that there would be a massive increase in pharmaceutical research and development spending -- which is now producing great results, with numerous innovative therapies entering the market in just the past two years.
For those wondering why shares of Amylin were down on a day that it received approval to market a new drug, it is because Byetta already received a positive opinion for marketing by the EMEA back in September, so its approval was never in doubt. Now that it has been formally approved, though, Amylin and marketing partner Eli Lilly
Sales of Byetta in the U.S. have approached nearly $300 million in the first nine months of the year. The disease is less prevalent in western Europe than the U.S., and reimbursement rates will most likely be less as well. But opening up these markets will still result in meaningful Byetta revenue growth to Amylin, even with strong competing drugs on the horizon.
For more on Amylin, check out the following articles:
Interested in biotech companies? So are the Fools working on our Motley Fool Rule Breakers newsletter service. You can check it out by taking a free 30-day trial today. Eli Lilly is an Income Investor pick.